$HUM

Stockholders of record will receive Humana’s cash payment Nov. 27

Humana (HUM) declared a quarterly cash dividend of $0.885 per share, approved by its Board of Directors. Stockholders of record will receive the payment on November 27. Humana is a leading U.S. healthcare company.

Original reporting
Published Sep 2, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$HUM
Neutral
high confidence
Mentioned
$HUM
Relevance
5/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$HUMNeutralLow
01

Why it matters

The dividend announcement provides a small income incentive but does not indicate a strategic shift.

02

Market read

A routine dividend declaration with modest size; limited trading relevance.

03

What to watch

Potential future rate‑sensitive cost pressures on Humana's Medicare business.

Relevance 5/10Novelty 6/10Timing: announcement today

Background

Humana is a major U.S. health insurer and Medicare Advantage provider.

Company-level read

Ticker impact

$HUMNeutralHigh confidence
Context

Humana announced a quarterly cash dividend of $0.885 per share, payable to shareholders of record on Nov. 27.

Expected impact

Small upside or stability as dividend‑focused investors may buy, but limited price move.

Evidence & confidence

Dividend announcements are routine corporate actions; the amount is modest and does not signal major strategic change.

Market effects

Reinforces dividend‑yield focus in the healthcare insurance sector.

Minimal impact on broader U.S. markets.

Limited; only relevant to investors tracking U.S. health insurers.

Counterpoint

The dividend is modest and may not offset broader industry headwinds.

Key entities

  • Humana Inc.

    U.S. health insurance and care services provider.

Related articles

$UNHHighAI 8/10

Health Insurer Stocks Are Soaring As Companies Get A Handle On Costs

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

$CNCMedAI 8/10

CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

Med

Glenmark USA Agrees to USD 15.28 Mn Settlement With Humana Over Generic Drug Antitrust Claims

Glenmark Pharmaceuticals said its U.S. subsidiary, Glenmark USA, agreed to settle with Humana Inc. for $15.28 million, including interest, to resolve antitrust and consumer protection claims over alleged generic drug price-fixing and market allocation. Glenmark USA denies all allegations. The company said the amount is already provided for in its financials and expects no significant financial impact.

Med

Glenmark’s U.S. unit settles Humana antitrust case for $15.3 mln

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.

MedAI 8/10

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

Glenmark Pharmaceuticals Ltd said its US unit, Glenmark Pharmaceuticals Inc., agreed to pay Humana Inc. $15.28 million to settle antitrust litigation over alleged price-fixing and market allocation in generic drugs. Glenmark said it denies all allegations and the settlement is not an admission of liability. The payment is in two installments and already provided for in its financials.